A recombinant plasmid, a recombinant lentiviral vector, a stable cell line, and a construction method and application thereof
A recombinant plasmid with a 3HRE-hCMVmp DNA sequence integrated into a lentiviral vector addresses the limitations of luciferase imaging by providing stable and proportional fluorescence for quantifying HIF1 activation in tumor cells, enabling accurate monitoring of tumor hypoxia and therapeutic responses.
Patent Information
- Application Number
- CN202210870435.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-22
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-07-22
AI Technical Summary
Current luciferase imaging technology in bioluminescence imaging (BLI) is limited by semi-quantitative research, non-proportional fluorescence intensity, and sensitivity affected by tissue depth and endogenous/exogenous factors, making it difficult to achieve absolute quantification and standardization.
A recombinant plasmid containing a 3HRE-hCMVmp DNA sequence is integrated into a lentiviral vector, which is used to create a stable cell line that enhances hypoxic response, providing stable and proportional fluorescence values to monitor HIF1 activation levels in tumor cells.
The recombinant plasmid enables quantitative and qualitative evaluation of HIF1 activity in tumor cells, reducing errors and enhancing sensitivity, allowing real-time monitoring of tumor hypoxia processes and therapeutic effects.
Smart Images

Figure CN116064675B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a recombinant plasmid, a recombinant lentiviral vector, a stably transfected cell line, and a construction method and application thereof. Background Art
[0002] Studies have shown that due to the rapid growth of malignant tumors, their own cells are in a state of hypoxia for a long time. Hypoxia plays an important role in the metabolism, molecular genetics, pathophysiology and other aspects of tumor cells. Long-term hypoxia can not only slow down cell metabolism, reduce genome stability, induce gene mutations and deletions, induce DNA chain breaks, and reduce cell physiological functions, but also play an important role in the occurrence and development of tumors, which can lead to resistance to radiotherapy and chemotherapy, "irritate" tumors and cause tumor recurrence, invasion and metastasis, etc. Hypoxia-inducible factors (HIFs) are a type of transcriptional regulatory factors activated by cells to adapt to hypoxic environments. Since their discovery, HIFs have been shown to play a key regulatory role in a variety of physiological and pathological processes, especially in the hypoxic microenvironment of tumor cells. Hypoxia-inducible factors 1 (HIF1) can activate the expression of target genes by binding to hypoxia response elements (HRE) in the 5' non-coding region of downstream cytokines. HRE, as a recognition element for HIF1 binding to the promoter region of downstream cytokines, can be used to monitor the activation level of HIF1, providing a new approach for the study of HIF1-related hypoxia response pathways.
[0003] Bioluminescence Imaging (BLI) is a molecular imaging technology that can use biological light signals to correlate specific physiological or pathological cell activities in living animals, and track and monitor the dynamic changes of cells, proteins, and genes in real time. This non-invasive technology can quantify cell processes and detect the dynamic changes of biological macromolecules in the same animal under the same spatial and temporal conditions. In vivo bioluminescence imaging technology usually uses a luciferase reporter gene system, placing the luciferase reporter gene under the control of the target gene promoter. It is the most commonly used method to construct a luciferase reporter system. This method uses tissue-specific promoters that are even strictly dependent on a specific protein. It can track a cell process or the transcriptional activity of a specific protein in small animals based on the expression of luciferase. Specific cancer cell processes and labeled molecular events can be observed through luciferase reporter genes, which can help early detection of cancer and related research such as understanding the origin of cancer, the role of the immune system, tumor angiogenesis, tumor invasion, and cancer treatment. In recent years, many studies have used BLI technology combined with luciferase reporter system to monitor cancer growth in animal models. These tumor animal models can simulate high-mortality cancer processes, including brain cancer, prostate cancer, pancreatic cancer, breast cancer and liver cancer. For example, in 2002, Vooijs et al. first constructed a tumor luminescent mouse model to study the occurrence of pituitary tumors. Subsequently, another research team used the promoter-luciferase transgenic (Ef-Luc) mice of the transcription activator E2F1 related to cell cycle and apoptosis to cross with the human glioma mouse model to establish an oligodendroglioma model. In 2006, Lyons et al. used the probasin promoter to regulate the prostate-specific expression of SV40 large T antigen, induced prostate hyperplasia in mice, and eventually developed into advanced lesions-tumor cell metastasis. If the promoter of the PSA gene specifically expressed in prostate epithelial cells is used to regulate the expression of the luciferase gene on the basis of this mouse model, the effect of androgen blockade on prostate tumor growth can be tracked for a long time. In 2011, Lu et al. used endogenous alpha-fetoprotein (alpha- In the same year, Park et al. also reported a mouse model that used the AFP promoter to regulate luciferase expression. Both mouse models can monitor chemically induced liver cancer using BLIs technology.However, the current luciferase imaging technology still has certain limitations in analyzing imaging results. For example, the sensitivity of luciferase luminescence is affected by many parameters. One of the key influencing factors is the depth of luciferase-labeled cells in the animal body. Although the light produced by luciferase-catalyzed substrates has strong penetrating power and can penetrate the tissues of small animal models, studies have found that the light intensity decreases by about 10 times for every additional centimeter of tissue depth. Secondly, its bioluminescent signal value is not completely proportional to the number of cells. Each step of the reaction between luciferase and substrate may be affected by endogenous and exogenous factors, resulting in errors. There are even differences in the amount of luciferase, luciferin, and auxiliary factors such as ATP in different cells or tissues. Therefore, the current use of luciferase imaging can generally only be used for semi-quantitative research, and its fluorescence intensity is weak, difficult to detect, and difficult to normalize and standardize. Summary of the invention
[0004] In order to solve the above technical problems, the purpose of the present invention is to provide a recombinant plasmid, a recombinant lentiviral vector, a stable cell line and a construction method and application thereof, so as to solve the defects existing in the prior art.
[0005] In order to achieve the above technical effects, the present invention adopts the following technical solutions:
[0006] In a first aspect, the present invention provides a recombinant plasmid, wherein the recombinant plasmid contains a 3HRE-hCMVmp DNA nucleotide sequence as shown in SEQ ID NO:1.
[0007] Furthermore, the nucleotide sequence of the recombinant plasmid is shown in SEQ ID NO:2.
[0008] Furthermore, the recombinant plasmid is obtained by using pLenti-CMV-Puro-Luc as the plasmid vector backbone, and replacing the CMV promoter fragment at the position of 1bp to 508bp in the plasmid vector backbone with the 3HRE-hCMVmp DNA nucleotide sequence shown in SEQID NO: 1, and the nucleotide sequence of the obtained recombinant plasmid is shown in SEQID NO: 2.
[0009] In a second aspect, the present invention also provides a method for constructing a recombinant plasmid, which specifically comprises the following steps:
[0010] S1: Amplify the 3HRE-hCMVmp DNA nucleotide sequence;
[0011] S2: Double-digest 3HRE-hCMVmp DNA with Ndel and Mlul, and then use DNA gel recovery and purification kit to recover and amplify the 3HRE-hCMVmpDNA nucleotide sequence with restriction sites;
[0012] S3: After the plasmid vector skeleton pLenti-CMV-Puro-Luc is expanded and cultured, the plasmid is extracted, and the target fragment is recovered after double restriction digestion with Ndel and Mlul. Then, the 3HRE-hCMVmpDNA fragment with restriction sites is integrated into the target fragment to obtain a recombinant plasmid.
[0013] Furthermore, the primer pair used to amplify the 3HRE-hCMVmp DNA nucleotide sequence in S1 is as follows:
[0014] Primer 1: 5'-TATGGGATCCTGTCACGTCCT-3', upstream 5' end primer,
[0015] Primer 2: 5'-CGTGTCGACAGCTCTGCTT-3', which is the downstream 3' end primer.
[0016] In a third aspect, the present invention further provides a recombinant lentiviral vector, which is obtained by transfecting 293T cells with a recombinant plasmid obtained by the above-mentioned recombinant plasmid, or by transfecting 293T cells with a recombinant plasmid obtained by the above-mentioned recombinant plasmid construction method.
[0017] In a fourth aspect, the present invention further provides a stable cell line, wherein the stable cell line is obtained by infecting animal cells with the above-mentioned recombinant lentiviral vector.
[0018] Furthermore, the animal cell is any one of human cervical cancer HeLa cells, HeLa-ADR resistant cells, human non-small cell lung cancer A549 cells or esophageal cancer EC109 cells, and preferably human cervical cancer HeLa cells and non-small cell lung cancer A549 cells.
[0019] In a fifth aspect, the present invention further provides an application, specifically including the application of the above-mentioned recombinant plasmid, the construction method of the above-mentioned recombinant plasmid, the above-mentioned recombinant lentiviral vector, or the above-mentioned stably transformed cell line in the preparation of diagnostic reagents.
[0020] Furthermore, the diagnostic reagent is used to track and monitor the HIF1 activation level of human or mammalian cells in vivo.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] First, luciferase imaging in the prior art can generally only conduct semi-quantitative research, and cannot achieve absolute quantification, and is difficult to normalize and standardize. Moreover, its bioluminescence signal value is not completely proportional to the number of cells. Each step of the reaction between luciferase and substrate may be affected by endogenous and exogenous factors, resulting in errors. Even in different cells or tissues, there are differences in the amount of luciferase, luciferin, and auxiliary factors such as ATP. The recombinant plasmid provided in the present application enhances the hypoxic response of the recombinant plasmid so that the same amount of cells can achieve a stronger fluorescence value at the cell experimental level. It can be used to monitor the effects of drugs or other means on the HIF1 level in tumor cells at different time points. Its fluorescence value can be stable and proportional to the number of cells, which can effectively reduce the error of the in vivo bioluminescence imaging results, and then achieve qualitative and quantitative evaluation of the change level of HIF1 activity in tumor cells.
[0023] Secondly, due to the defects of the prior art caused by the limitation of the depth of luciferase-labeled cells in the animal body due to luciferase imaging, the recombinant plasmid provided by the present invention enables the recombinant plasmid to show more stable fluorescence value quantitative analysis at the cellular level, with relatively smaller errors, and shows stronger fluorescence values than other reporter genes under the premise of the same cell amount, and shows stronger hypoxic response and higher sensitivity at the in vivo tumor model level, thereby realizing the monitoring of the activation level of HIF1, providing a new approach for the study of HIF1-related hypoxia response pathways.
[0024] Thirdly, the promoter fragment of a lentiviral plasmid provided by the present invention is smaller, the hypoxia response sensitivity is high, the fluorescence signal is strong, the fluorescence value and the fluorescence brightness are stable, and a variety of cancer cells carrying the plasmid can quickly respond to the hypoxic environment and efficiently express Luc. The stably expressed cancer cell line can use bioluminescence imaging technology to realize real-time monitoring of tumor hypoxia process and evaluation of the therapeutic effect of anti-tumor compounds. Experiments show that the in vivo BLI monitoring signal is good, which can realize the visual tracking and monitoring of HIF1 activity in small animal in vivo tumor models. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 is the map of the inserted DNA sequence 3HRE-hCMVmp;
[0026] Figure 2 This is the map of the recombinant plasmid pLenti-HRE-hCMVmp-Puro-Luc;
[0027] Figure 3The electrophoresis diagram of the restriction digestion results of HRE-hCMVmp-Luc viral plasmid (Note: Lane 1 in the figure is the viral plasmid double-digested by Sall and BamH I, Lane 2 is the viral plasmid single-digested by BamH I, Lane 3 is the viral plasmid single-digested by Sall, and Lane 4 is the intact viral plasmid control);
[0028] Figure 4 is the sequencing result of the inserted 3HRE-hCMVmp fragment;
[0029] Figure 5 The results of the hypoxia validation experiment of the recombinant plasmid pLenti-HRE-hCMVmp-Puro-Luc;
[0030] Figure 6 This is the fluorescence detection result during the screening of Hela-HRE-hCMVmp-Luc stable cell lines;
[0031] Figure 7 The IVIS test results of Hela-HRE-hCMVmp-Luc stable cell line (cell quantity is 1×104);
[0032] Figure 8 The IVIS test results of A549-HRE-hCMVmp-Luc stable cell line (cell quantity is 1×104);
[0033] Fig. 9 This is the fluorescence sensitivity test result of stably transfected cells in tumor models;
[0034] Fig.10 This is the tumor fluorescence observation result of the nude mouse subcutaneous tumor animal model;
[0035] Fig.11 Verify the results for cell-level experiments;
[0036] Fig.12 The results were verified by animal experiments (n=3). DETAILED DESCRIPTION
[0037] The embodiments of the technical solution of the present invention will be described in detail below in conjunction with the accompanying drawings. The following examples are only used to more clearly illustrate the technical solution of the present invention, and are therefore only used as examples, and cannot be used to limit the scope of protection of the present invention. It should be particularly noted that the following examples are only used to explain the present invention and are not used to limit the scope of the present invention. At the same time, the test methods used in the following examples are conventional methods unless otherwise specified; the materials, reagents, etc. used, unless otherwise specified, are reagents and materials that can be purchased and obtained from commercial channels.
[0038] Example 1 Construction of HRE-hCMVmp-Luc lentiviral vector:
[0039] 1.1 Construction of recombinant plasmid
[0040] The lentiviral vector plasmid pLenti-CMV-Puro-LUC (w168-1) (addgene #17477) containing a firefly luciferase reporter gene, a puromycin selection system, and two pairs of restriction sites of BamHI and SalI, NdeI and Mlul at both ends of the promoter was selected as the plasmid vector backbone. Then a DNA sequence 3HRE-hCMVmpDNA (145 bp) was artificially synthesized, which contained the 3HRE element fragment sequence at the position of 5749 bp to 5772 bp in the pGL2-HRE-Luc (Plasmid #26731) plasmid, the hCMVmp promoter fragment sequence in the 5HRE-GFP plasmid (Plasmid #46926), and the restriction sites of NdeI and BamHI, SalI and Mlul. The artificially synthesized DNA fragment was amplified by PCR, and the amplification primers were designed as follows:
[0041] Primer 1 is the upstream 5' primer: 5'-TATGGGATCCTGTCACGTCCT-3'
[0042] Primer 2 is the downstream 3′ end primer: 5′-CGTGTCGACAGCTCTGCTT-3′;
[0043] The synthetic DNA fragment was used to replace the original CMV promoter fragment from 1 bp to 508 bp in the plasmid vector backbone pLenti-CMV-Puro-Luc (w168-1) (Plasmid #17477) to construct a recombinant plasmid, and the obtained recombinant plasmid was named pLenti-HRE-hCMVmp-Puro-Luc. The specific method is as follows:
[0044] The 3HRE-hCMVmpDNA fragment with restriction sites was recovered and amplified using a DNA gel recovery and purification kit, and the plasmid vector backbone pLenti-CMV-Puro-Luc was expanded and cultured, and the plasmid was extracted. The target fragment was recovered after double digestion with Ndel and Mlul, and the synthesized DNA fragment was cloned into the pLenti-CMV-Puro-Luc vector after digestion through the same restriction sites to obtain the recombinant plasmid.
[0045] The inserted DNA sequence 3HRE-hCMVmp (145 bp) and the structural schematic diagram of the recombinant plasmid pLenti-HRE-hCMVmp-Puro-Luc are shown in the following figures: Figure 1 and Figure 2 shown.
[0046] 1.2 Preparation of lentiviral shuttle plasmid and its auxiliary packaging vector plasmid;
[0047] After replacing the medium of 293T cells with a confluence of 80%, two EP tubes were taken, physiological saline was added, and they were marked as tube A and tube B. PEI was added to tube A and vortexed thoroughly, and the target plasmid pLenti-HRE-hCMVmp-Puro-Luc and two auxiliary plasmids pSPAX2 and pMD2.G were added to tube B, with a total of 24 μg of three plasmids. The medium was replaced 12 hours after transfection, and the cell supernatant was collected 48 hours and 72 hours after the medium was replaced. The supernatant was centrifuged at 4500g for 20 minutes, and the supernatant was taken and filtered using a 0.45 μm filter. After filtration, the virus was concentrated using the PEG-8000 method to obtain the HRE-hCMVmp-Luc lentiviral vector.
[0048] Example 2 Identification and Functional Verification of Recombinant Plasmid pLenti-HRE-hCMVmp-Puro-Luc:
[0049] 2.1 To verify whether the viral plasmid has been successfully inserted into the 3HRE-hCMVmp fragment carrying the restriction site, the viral plasmid was double-digested with SallHI and BamHI. The electrophoresis results are as follows: Figure 3 shown.
[0050] Figure 3 The results showed that Sall and BamHI successfully digested the viral plasmid into linear fragments, proving that the restriction site had been successfully introduced into the viral plasmid. However, because the inserted fragment was too small, the difference in plasmid length after double digestion and single digestion could not be distinguished by agarose electrophoresis. Therefore, the inserted fragment was sequenced to further verify the construction results. The verification results are shown in Figure 4 As shown, Figure 4 The sequencing results showed that the 3HRE-hCMVmp fragment was successfully inserted into the lentiviral vector plasmid and the sequence was consistent with the expected results.
[0051] 2.2 Functional verification of the recombinant plasmid HRE-hCMVmp-Luc through cell hypoxia experiment
[0052] In this example, a cell validation experiment of hypoxia response was carried out using the HRE-Luc / Rluc system of human cervical cancer HeLa cells, HeLa-ADR resistant cells, human non-small cell lung cancer A549 cells and esophageal cancer EC109 cells. The experimental method is as follows:
[0053] 2.2.1 Determine the mass ratio of HRE-hCMVmp-Luc and pGL3-Rluc plasmids during co-transfection
[0054] According to the requirements of lip3000 transfection reagent and the results of literature review, the total amount of DNA for double plasmid co-transfection was first controlled at 100 ng / well (96-well plate). The recombinant plasmid HRE-hCMVmp-Luc and the control plasmid Rluc were transfected into cells at a ratio of 50 ng:50 ng (1:1), 84 ng:17 ng (5:1), 90 ng:9 ng (10:1), and 100 ng:2 ng (50:1). The firefly fluorescence and Renilla fluorescence values were detected, and the relative fluorescence activity of the firefly fluorescence / Renilla fluorescence value was calculated.
[0055] The experimental results are shown in Table 1. Under the condition of 1:1 mass ratio, the fluorescence intensity of Luc and Rluc reaction in the cell after co-transfection of recombinant plasmid HRE-hCMVmp-Luc and pGL3-Rluc plasmid reached 104 and 105 orders of magnitude, respectively, and the latter was 20 times higher than the former. When the transfection amount of recombinant plasmid HRE-hCMVmp-Luc was increased according to the mass ratio of 5:1, 10:1, and 50:1, and the transfection amount of pGL3-Rluc plasmid was reduced at the same time, the fluorescence intensity of the former was reduced by about 1 order of magnitude after co-transfection, and the fluorescence intensity of the latter was reduced by 3 orders of magnitude, which was almost undetectable. Combined with the above results, the recombinant plasmid HRE-hCMVmp-Luc and pGL3-Rluc plasmid were selected as the optimal experimental conditions for co-transfection at 50ng:50ng (1:1).
[0056] Table 1 Effect of different ratios of recombinant plasmid HRE-hCMVmp-Luc and pGL3-Rluc plasmid on the results of co-transfection
[0057]
[0058] 2.2.2 Determination of Lipo3000 reagent dosage
[0059] According to the requirements of LipofectamineTM 3000 reagent, Lipo3000 can be transfected at 0.15μL / well or 0.3μL / well. The specific volume to be used needs to be explored according to the actual situation. In order to find the appropriate amount of lipo3000 transfection reagent, transfections of 0.15μL / well and 0.3μL / well were performed at the same time. The test results are shown in Table 2. Finally, Lipo3000 reagent was added at 0.15μL / well, and subsequent experiments were performed using this condition for transient transfection.
[0060] Table 2 Effect of transfection reagent dosage on results
[0061]
[0062] 2.2.3 Verification of cellular hypoxic response
[0063] The hypoxia-responsive dual-luciferase reporter gene HRE-Luc / Rluc cell system was successfully constructed. In theory, when cells are under hypoxic conditions, HIF1α expression will be activated, and the activated hypoxia response factor can enhance Luc expression through the HRE hypoxia response element. In this system, the chemiluminescence of HRE-Luc can reflect the activation level of HIF1α in cells, and the constitutive expression of Rluc can be used as an internal reference for transfection efficiency to eliminate the differences in cell number and transfection efficiency. After the chemiluminescence detection of the HRE-Luc / Rluc dual-luciferase reporter gene, the ratio of the two fluorescence values can more reliably reflect the activation level of HIF1α in cells. In this study, we conducted a cell verification experiment of hypoxia response in the HRE-Luc / Rluc system of human cervical cancer HeLa cells, HeLa-ADR resistant cells, human non-small cell lung cancer A549 cells and esophageal cancer EC109 cells.
[0064] The experiment was divided into a normoxic control group and a hypoxic experimental group. The normoxic control group was cultured under 25% O2 concentration conditions, and the hypoxic experimental group was cultured under 1% O2 concentration conditions. Cells were collected and luciferase bioluminescence was detected at 12h, 18h, and 24h of culture. The results of the hypoxia experiment are shown in Figure 5 As shown, the experimental results confirmed that the relative fluorescence activity of the recombinant plasmid under hypoxia conditions was significantly higher than that under normoxia by 2-8 times, and as the hypoxia time increased, the hypoxic fluorescence activity also continued to increase, confirming that the viral plasmid had hypoxia response activity.
[0065] The above experiments show that the constructed HRE-hCMVmp-Luc recombinant plasmid can be used to observe the hypoxic activation response of HIF1.
[0066] Example 3 Construction of Hela-HRE-hCMVmp-Luc stable cell line:
[0067] 3.1 This example uses HeLa cells as an example to construct a Hela-HRE-hCMVmp-Luc stable cell line, as follows:
[0068] 3.1.1 Determination of Puromycin Screening Concentration
[0069] Puromycin was used as the screening agent, and Hela cells were plated into 24-well cell plates, with 5×10 4 ~1×10 5 When the confluence of Hela cells reaches 50-60%, use the selection medium containing different concentrations of puromycin, change the medium every two days, and after 7-10 days of screening, use 0.4% trypan blue dye to observe cell survival.
[0070] Based on the observation results of cell survival, the puromycin concentration that just caused the cells to basically die after 7-10 days of selective culture was determined as the final screening concentration, that is, the puromycin concentration was 4 μg / ml.
[0071] 3.1.2 Determination of virus infection
[0072] (1) Determination of polybrene dosage: The commonly used working concentration is 6-8 μg / mL, and it is best if there is no obvious toxic reaction in the cells within 24 hours. The final dosage was determined to be 8 μg / mL.
[0073] (2) Determination of virus infection amount: Hela cells were plated in 96-well cell plates, with 5,000-10,000 cells inoculated in each well. After the cell confluence reached 30%-50%, the lentiviral stock solution was diluted to concentrations of 1, 10- 1 、10- 2 , 10- 3, 10- 4 、10- 5 、10- 6 、10- 7 , add the above virus dilution and polybrene to 96-well plate, 100ul is added to each well, and the virus fluorescence results are detected three days later. Each experiment is repeated 3 times and the average value is calculated. The experimental results are shown in Table 3:
[0074] Table 3 Efficiency of Hela cells infected with different virus doses
[0075]
[0076] From the above results, it can be seen that the virus infection efficiency is very high. 3 The fluorescence can still reach the million level, but considering the transfection efficiency and saving the amount of virus, the dilution factor is 10- 2 To stabilize the amount of infectious virus.
[0077] 3.1.3 Construction of Hela-HRE-hCMVmp-Luc stable cell line
[0078] HeLa cells were used as experimental materials, and the lentiviral vector prepared in Example 1 was used to infect the cells. The amount of polybrene used during cell infection was 8 μg / mL. Three days after cell infection, a selection medium containing 4 μg / mL puromycin was added for stable cell screening. The selection medium containing puromycin was replaced once every two days. The first Luc fluorescence value fluorescence activity detection was performed on the 7th day after the addition of puromycin, and then the cell Luc fluorescence value fluorescence activity was detected every 7 days. The cells that survived 21 days after the addition of puromycin were Hela-HRE-hCMVmp-Luc stable cell lines. The activity detection results during the screening process are shown in FIG. Figure 6 shown.
[0079] After the constructed Hela-HRE-hCMVmp-Luc stably transfected cell line was hypoxic for 24 hours, the fluorescence value was detected by IVIS small animal live imaging. The detection results are as follows: Figure 7 shown.
[0080] 3.2 This example is described using human non-small cell lung cancer A549-HRE-hCMVmp-Luc cells as an example, specifically:
[0081] The A549-HRE-hCMVmp-Luc cell line was constructed according to the method in 3.1. The constructed A549-HRE-hCMVmp-Luc stable cell line was subjected to hypoxia for 24 hours and the fluorescence value was detected by IVIS. The detection results are as follows: Figure 8 shown.
[0082] Example 4 Establishment of nude mouse tumor model and BLI monitoring
[0083] 4.1 Fluorescence sensitivity detection of stably transfected cells in tumor models
[0084] The Hela-HRE-hCMVmp-Luc stable cell line constructed in Example 3 was expanded and collected, and injected subcutaneously at four points in nude mice for 10 6 , 10 5 , 10 4 , 10 3 cells and immediately observed the luminescence. The experimental results are as follows Fig. 9 As shown in the experimental results, for the nude mouse model, a single subcutaneous injection of 10 5 Cell number, a trace amount of Luc fluorescence signal can be detected immediately, while a single injection of 10 6 After the cells were stained, a very obvious Luc fluorescence signal could be detected immediately.
[0085] 4.2 Establishment of nude mouse subcutaneous tumor animal model and tumor fluorescence observation
[0086] According to the results of experiment 4.1, the appropriate injection volume for stable transfection cells was determined, and the number of cells injected per time was 10 6 Hela-HRE-hCMVmp-Luc stably transfected cells were collected and injected subcutaneously into nude mice. The hypoxic fluorescence activity of nude mice was observed on days 8, 11, 14, 17, and 20 of tumor growth. The experimental results are as follows: Fig.10 As shown, the experimental results show that the Hela-HRE-hCMVmp-Luc stable cell line can also maintain a high luminescence intensity in the animal body.
[0087] Example 5 Application of nude mouse tumor model in chemotherapy
[0088] Melatonin (N-acetyl-5-methoxytryptamine, Melatonin) is an endogenous hormone, the main function of which is to regulate the biological clock, anti-oxidation, improve endothelial dysfunction, etc., and there is experimental evidence that it can affect the formation and progression of tumors by participating in a variety of molecular and cellular processes, and play an important role in the prevention and treatment of cancer, such as inhibiting the activity of HIF1, thereby participating in anti-tumor angiogenesis. Therefore, this example takes the non-small cell lung cancer A549-HRE-hCMVmp-Luc stable cell tumor model as an example, and selects melatonin as the chemotherapeutic drug in the experiment.
[0089] 5.1 Cell-level experimental verification
[0090] A549-HRE-hCMVmp-Luc stable transfected cells under normoxic and hypoxic conditions were treated with complete culture medium supplemented with 0 μM, 100 μM, 400 μM, and 800 μM melatonin, respectively. The experimental results are shown in Fig.11 As shown, the results showed that 6 hours after the start of the experiment, the fluorescence value of the hypoxic group without melatonin was significantly higher than that of the normoxic group, but the fluorescence value of the hypoxic group cells decreased significantly with the increase of melatonin concentration; in contrast, there was no significant change in fluorescence value between the normoxic group without drug addition and the drug addition group, suggesting that HRE-hCMVmp-Luc stably transfected cells are not only highly sensitive to the HIF1 hypoxic response, but can also be used to evaluate the effects of chemotherapeutic drugs on the activity level of the HIF1 hypoxic response.
[0091] 5.2 Animal experiment verification
[0092] One week after the formation of subcutaneous tumors in nude mice established with non-small cell lung cancer A549-HRE-hCMVmp-Luc stable cells, the nude mice were treated with 50 mg / kg melatonin and used as the experimental group, while the blank control group was not given the drug. The animal in vivo imaging system IVIS was used to observe the changes in the LUC fluorescence signal of the tumors of the two groups of nude mice at 0h, 6h, and 24h after the administration of the experimental group. The experimental verification results are as follows Fig.12 As shown, the experimental results showed that within 24 hours, the fluorescence signal of the tumor in the nude mice treated with the drug was significantly reduced, while there was no significant change in the fluorescence signal intensity of the tumor in the nude mice in the blank control group.
[0093] In this example, although the number of nude mice in the experiment was limited, it was preliminarily demonstrated that the pLenti-HRE-hCMVmp-Puro-Luc recombinant plasmid constructed by the present invention is very sensitive to HIF1 hypoxia response, and has high practical value in the research and application of monitoring the activation level of hypoxia-inducible factor 1 in cells and in vivo.
[0094] The above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the present invention. Although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the purpose and scope of the technical solutions of the present invention, which should be included in the scope of the claims of the present invention. The techniques, shapes, and structural parts not described in detail in the present invention are all known technologies.
Claims
1. A recombinant plasmid, characterized in that: The recombinant plasmid contains the 3HRE-hCMVmp DNA nucleotide sequence shown in SEQ ID NO: 1, and the nucleotide sequence of the recombinant plasmid is shown in SEQ ID NO:
2.
2. The method for constructing a recombinant plasmid according to claim 1, characterized in that: The following steps are involved: S1: Amplify the 3HRE-hCMVmp DNA nucleotide sequence; S2: Double-digest 3HRE-hCMVmp DNA with Ndel and Mlul, and then use DNA gel recovery and purification kit to recover and amplify the 3HRE-hCMVmpDNA nucleotide sequence with restriction sites; S3: After the plasmid vector skeleton pLenti-CMV-Puro-Luc is expanded and cultured, the plasmid is extracted, and the target fragment is recovered after double restriction digestion with Ndel and Mlul. Then, the 3HRE-hCMVmpDNA fragment with restriction digestion sites is integrated into the target fragment to obtain a recombinant plasmid.
3. The method for constructing a recombinant plasmid according to claim 2, characterized in that: The primer pairs used to amplify the 3HRE-hCMVmpDNA nucleotide sequence are as follows: Primer 1: 5'-TATGGGATCCTGTCACGTCCT-3', upstream 5' end primer, Primer 2: 5'-CGTGTCGACAGCTCTGCTT-3', which is the downstream 3' end primer.
4. A stable cell line, characterized in that: The stable cell line is obtained by infecting animal cells with the recombinant plasmid described in claim 1 or a recombinant plasmid constructed by the construction method of any one of claims 2-3; the animal cells are any one of human cervical cancer HeLa cells, HeLa-ADR resistant cells, human non-small cell lung cancer A549 cells or esophageal cancer EC109 cells.
5. A use of the recombinant plasmid according to claim 1, or the method for constructing the recombinant plasmid according to any one of claims 2 to 3, or the stably transformed cell line according to claim 4 in the preparation of a diagnostic reagent, characterized in that: The diagnostic reagent is used for tracking and monitoring the HIF1 activation level of human or mammalian cells in vivo.
